Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a malaria drug boost leukemia treatment?

NCT ID NCT07022743

Disease control Sponsor: Obafemi Awolowo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial in Nigeria tests whether adding artesunate, a malaria drug, to the standard CML medication imatinib can improve treatment outcomes. 75 adults with chronic myeloid leukemia will receive either imatinib alone or imatinib plus artesunate. The goal is to see if the combination leads to better molecular remission and is safe for long-term use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
imatinib and artesunate combination
What this could lead to
If it works, this could offer a more affordable and effective treatment option for CML patients, especially in low-income countries where second-line drugs are unavailable.
What could go wrong
This is a small Phase 2 trial with only 75 participants, so results may not apply to everyone. Artesunate's long-term safety for CML is not yet proven, and the combination may not work better than imatinib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed chronic phase CML patients * Patients with sub-optimal response to imatinib therapy * Ages between 18 years and 85 years with written informed consent Exclusion Criteria: * Patients with documented hypersensitivity to artesunate * Patients with cardiovascular disease, pregnancy and inability to give consent will be excluded. * Patients currently on any medication(s) that may interact with imatinib or affect its pharmacokinetics parameters (like rifampicin and ketoconazole) will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic myeloid leukemia (CML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic myeloid leukemia (CML)

Contacts and locations

Locations

  • Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife

    Ile-Ife, Osun State, 3408, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.